Joshua Ondatje is a clinical research leader with 20 years of experience across CRO and biopharma, guiding global teams through all phases of clinical operations, drug development, medical devices, and digital therapeutics. His therapeutic background spans oncology, rare disease, cardiology, and CNS.
As Director of Clinical Study Management at BeiGene/BeOne Medicines, he led global Phase I–III programs, contributed to the FDA approvals of Brukinsa and Tevimbra, and earned the Patients First Award three years running (2023–2025). He is known for operational excellence, strategic partnership building, and patient‑centric delivery.
A champion of quality, efficiency, and compliance, Joshua has authored SOPs, driven inspection readiness, led internal audits, and embedded quality‑by‑design across workflows. His prior role as Executive Director of Project Management, Oncology at Worldwide Clinical Trials strengthened his expertise in project delivery, financial oversight, strategy development, vendor management, and team leadership.
He holds a B.S. in Biology from UCLA and an MBA from National University. In 2019, he was named Clinical Researcher of the Year and Project Manager of the Year.
